AMRX Stock — Amneal Pharmaceuticals, Inc.

Up next

Next earnings call

Oct 26, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$3.12B

Trailing 12 months

Net income (TTM)

$157.36M

Trailing 12 months

Revenue growth YoY

+9.9%

Year over year

Operating margin

14.6%

Trailing 12 months

P / E (TTM)

36.3

Trailing earnings · reciprocal yield 2.8%

FCF yield

2.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$2.44B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.8%

Year over year · more shares

Price change (1Y)

+82.6%

Trailing year

Short interest

3.0%

Latest settlement · 4.9 days to cover

View all 114 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026

Q2 FY26

TL;DR. Amneal delivered Q2 revenue of $796 million (+10%), adjusted EBITDA of $206 million (+12%), and adjusted EPS of $0.30 (+20%), and raised 2026 guidance for revenue, adjusted EBITDA and adjusted EPS while successfully repricing its Term Loan B to lower interest costs, though a flood at an India facility is expected to dent results and AvKARE revenue declined.

Bullish

+ Specialty segment revenue grew 17% driven by Crexont, Brekiya and Unithroid
+ Affordable Medicines revenue grew 13% on complex portfolio strength and new launches
+ Adjusted gross margin expanded 60 bps to 46.2% on favorable mix and efficiencies
+ Successful Term Loan B repricing cuts interest rate by 50 bps and saves ~$12 million annually

Bearish

− AvKARE revenue declined 4% due to weakness in low-margin distribution
− Severe flooding at India facility expected to cost ~$20 million in negative impact
− Acquisition costs of $7.6 million in Q2 related to pending Kashiv deal
− Legal-related charges of $8.1 million in Q2 tied to antitrust class action litigation

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 14.5 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +21%

above

Price vs 50-day avg −2%

below

RSI (14) 45

neutral

MACD trend Negative

52-week position 83%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −4%

trailing

6-month return +46%

trailing

YTD return +38%

this year

Relative strength +31%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $18 › 200d $14 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +49 funds added

Insider flow Distributing

Net -$7.2M over 90 days · 100% sells

Short interest Rising

2.98% of float · ▲ +14.4% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

312 holders — near 3-yr high, broad support

Squeeze score 60

elevated · 0–100

Fundamentals

Strong

Revenue growth +8%

Y/Y

Gross margin 37%

expanding

EPS growth +158%

Y/Y

Free cash flow $269.9M

Valuation P/E 36.3

rich

Balance sheet $2.3B

net debt

Quant / Vol

risk profile

Moderate

Volatility 34%

annualized · 1-yr

Max drawdown −22%

past year

ATR 3.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 4

Latest guidance · from the Earnings Call filed Sep 30, 2021

CapEx expectation · not specified $50M – $60M

Prior guidance period ended · from the 8-K filed Aug 9, 2024

Net revenue · full year 2024 $2.7B – $2.8B

Adjusted EBITDA · full year 2024 $610M – $630M

Operating cash flow · full year 2024 $280M – $320M

Adjusted diluted EPS · full year 2024 $0.57 – $0.63

Capital expenditures · full year 2024 $60M – $70M

Guided vs delivered · last 4 settled

Net revenue full year 2024

guided $2.7B – $2.8B

guided $2.7B – $2.8B $2.79B In line

Total company net revenue 2022

guided $2.15B – $2.25B

guided $2.15B – $2.25B $2.21B In line

Revenues Q1 2022

guided $500M

guided $500M $497.63M Miss −0.5%

Net revenue full-year 2021

guided $2.1B

guided $2.1B $2.09B Miss −0.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+21% Bullish

Price vs 50-day avg

−2% Neutral

RSI (14)

45 Neutral

MACD trend

Negative Bearish

52-week position

83% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $18 › 200d $14 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +49 funds added

Insider flow Distributing

Net -$7.2M over 90 days · 100% sells

Short interest Rising

2.98% of float · ▲ +14.4% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

312 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $10 Now $17 · 83% Range high $19

vs 200-day avg +21% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AMRX Amneal Pharmaceuticals, Inc. this stock	$5.57B	+38.4%	+8.0%	36.3	3.0%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$66.37B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$58.92B	+18.3%	—	—	0.1%
GALDY Galderma Group AG/ADR	$45.51B	-5.8%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$42.37B	+16.5%	+4.3%	59.6	3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

312

% held: 51.2%
Net QoQ: +2.4M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

304

View

Short & Settlement

Short Interest Rising

Shares short

9.5M

Days to cover: 4.9d
Change: +1.2M sh

View

Short Volume

Short vol %

60%

As of: Sep 4, 2026

Short Total

View

Fails to Deliver

FTD shares

191

Value: $3.4K
As of: Aug 13, 2026

View

Off-Exchange

Off-exchange %

42.3%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$7.2M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Financials

Revenue (FY)

$3.0B

Net income (FY): $72.1M
EPS diluted: $0.22

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 10, 2026
This year: 17

View

Proposed Sales

Value

$2.9M

Shares: 168.6K
Filed: Aug 11, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 30, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
AMRX	-0.6%	-3.9%	+46.1%	-0.2%	+38.4%
SPY	+0.1%	-0.4%	+15.1%	+0.4%	+12.9%
vs SPY	-0.7%	-3.5%	+30.9%	-0.6%	+25.5%

AMRX · Amneal Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance